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“3M New Zealand Ltd., 250 Archers Road, Glenfield, Auckland and ‘Royal New Zealand College of 
General Practitioners Research Unit, Medical School, University of Otago, Dunedin, New Zealand 
Four types of corticosteroid inhaler devices are available in New Zealand for first-line treatment of asthma, 
including two aerosol systems [Autohaler @ (3M Healthcare Ltd, Loughborough, U.K.; 3M Pharmaceuticals 
(Australia Pty Ltd, Sydney, Australia) and MD1 (Glaxo Wellcome PLC, Ware, U.K.)] and two dry powder systems 
[Diskhaler@ (Glaxo Wellcome) and Turbuhaler@ (Astra AB, Sodertalje, Sweden)]. Rates of asthma-related health 
care consumption and treatment outcomes associated with use of the different inhalers are unknown. 
In this retrospective survey, asthma-related primary health care consultation and prescription patterns were 
compared in a large general practice population for each corticosteroid inhaler device prescribed as first-line 
treatment. An electronic search of a computerized clinical database yielded the medical records of 5704 patients with 
physician-diagnosed asthma who were prescribed either the Autohaler, Diskhaler, MD1 or Turbuhaler as their sole 
corticosteroid inhaler device in the previous 12 months. 
The mean daily inhaled corticosteroid dose was lowest for the Autohaler (569 pg day- ‘; 95% CI: 538-605) 
followed by the Diskhaler (638 ,ug day - ‘; 95% CI: 6099670) and MD1 (655 pug day- ‘; 95% CI: 638-673), and was 
highest for the Turbuhaler (990 pg day - ‘; 95% CI: 954-1029, P<O.OOl). A relatively high proportion of patients 
aged 1949 years in the Turbuhaler and Diskhaler groups (29% and 23%, respectively) received at least one inhaled 
corticosteroid prescription including a daily dose greater than 15OOpg compared with the MD1 group (4%). In the 
Diskhaler group the mean daily inhaled corticosteroid dose prescribed for adult patients was similar to that for the 
Turbuhaler group (904 pg day - r and 1058 pg day- ‘, respectively). 
These data suggest that in New Zealand the dry powder corticosteroid inhaler devices are prescribed for adults at 
significantly higher doses than the aerosol inhaler devices. Clinical databases of this type yield valuable information 
on drug utilization in large patient populations and usefully assess clinical prescribing practices. 
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Introduction 
Asthma is quite prevalent in New Zealand, and accounts 
for up to 4.5% of general practice consultations (1). In a 
recent national population survey, 8.5% of adults reported 
use of asthma medication in the previous 12 months (2). 
Guidelines for asthma management recommend titrated 
doses of inhaled corticosteroids as first-line treatment for 
the inflammatory component of asthma, use of beta- 
agonists for symptomatic relief, and oral corticosteroids to 
treat severe acute exacerbations (3). Treatment according to 
these guidelines is common practice in New Zealand where 
approximately 47% of patients with physician-diagnosed 
asthma have been reported to receive inhaled corticosteroid 
therapy, with 62% of these treated on a daily basis (4). 
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Four corticosteroid inhaler devices are available in New 
Zealand, of which two are aerosol delivery systems [the 
Autohaler@ (3M Healthcare Ltd, Loughborough, U.K.; 
3M Pharmaceuticals (Australia Pty Ltd, Sydney, Australia) 
and metered dose inhaler, or MD1 (Glaxo Wellcome 
PLC, Ware, U.K.)] and two are dry powder systems [the 
Diskhaler@ (Glaxo Wellcome) and Turbuhaler@ (Astra 
AB, Sodertalje, Sweden)]. None of these inhaler devices is 
suitable for use in all asthma patients, and there is increas- 
ing evidence that the drug delivery system used is an 
important determinant of the efficacy of inhaled cortico- 
steroid therapy (5-7). However, the extent to which the 
potential inhaler device-related differences in efficacy shown 
in clinical studies influence actual primary health care 
consumption and prescribing practices in this country is 
unknown. 
The aim of this retrospective analysis was to compare 
actual asthma-related prescription and health-care consul- 
tation patterns in a large general practice population for 
patients treated with each of the corticosteroid inhaler 
devices prescribed as first-line treatment. 
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Methods 
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DATA ANALYSIS 
BACKGROUND 
The asthma-related prescription and consultation data used 
in this survey were collected from the database of the Royal 
New Zealand College of General Practitioners (RNZCGP) 
Research Unit at the University of Otago in Dunedin, New 
Zealand, and analysed by investigators affiliated to this 
unit. The database includes computerized clinical records 
for 128 585 patients from 28 medical practices throughout 
New Zealand for a l-year period. This data set has been 
described elsewhere and shown to be representative of the 
general practice population in this country (8) and a valid 
research tool (9). 
DATA COLLECTION 
Patient records in the database were searched electronically 
to identify patients who had been prescribed an Autohaler, 
Diskhaler, MD1 or Turbuhaler as their sole corticosteroid 
inhaler device for the 1Zmonth period ending on 30 June 
1995. The records of these patients were searched further 
to identify all beta-agonist and oral corticosteroid 
prescriptions. 
Key search words were: beclomethasone [Becloforte@ 
(Glaxo Wellcome): Becotide@ (Glaxo Wellcome), 
Becodisk@ (Glaxo Wellcome), Respocort Autohale@’ (3M 
Healthcare), Diskhale? (Glaxo Wellcome)], terbutaline 
[Bricanyl Turbuhaler@ (Astra AB)], budesonide [Pulmicort 
Turbuhaler@ (Astra AB)], salbutamol [Ventolin@ (Glaxo 
Wellcome), Respolin Autohaler@ (3M Pharmaceuticals 
(Australia))], betamethasone [Betnesol@ (Glaxo Wellcome)] 
and prednisone (Douglas Pharmaceuticals Ltd and Apotex 
NZ Ltd, Auckland, NZ). Prescriptions for other asthma- 
related medications, including theophyllines and cromogly- 
Gates, were not sought because of their low usage in this 
country. 
Mean daily doses of inhaled corticosteroids were 
determined by identifying the dosage instructions for each 
prescription, and calculating the daily dose for the period of 
the prescription. If the prescription contained a range of 
dose directions, the minimum prescribed dose was 
recorded. 
Mean daily doses of beta-agonists were calculated from 
prescribed quantities and dose strength, and averaged 
over the entire study period. Beta-agonist volumes were 
calculated as salbutamol-equivalent doses to compensate 
for the differing potency of the different beta-agonists. The 
dose relationship used to calculate relative terbutaline to 
salbutamol potency was 25O:lOO (10-12). Mean oral steroid 
doses were also calculated from prescribed quantities and 
dose strength for the study period. Prescription data for 
prednisone and betamethasone were pooled for analysis 
because the latter agent comprised only 0.2% of the total 
number of oral steroid prescriptions identified. 
A consultation was defined as asthma-related if a 
prescription for asthma medication, an inquiry about 
asthma, or a peak flow reading was recorded in the case 
notes. 
Asthma-related prescription and consultation data were 
analysed in relation to the type of corticosteroid inhaler 
device prescribed. The data were also stratified according to 
age group to distinguish the potentially confounding effects 
of probable treatment differences in asthmatic children and 
adolescents and of chronic obstructive airways disease 
(COAD) in older patients. The age bands selected were 
under 6 years, 6-18 years, 19-49 years and 50 years and 
over. The data were analysed further in a subgroup of 
patients aged 1949 years who had received at least one 
inhaled corticosteroid prescription including a daily dose 
higher than 15OOpg. 
Ethical consent for this study was obtained from the 
Otago Ethics Committee of the Southern Regional Health 
Authority. 
STATISTICAL ANALYSIS 
Most of the data used for this analysis were positively 
skewed rather than normally distributed, so Student’s 
t-tests and one-way ANOVAs were not strictly valid. 
Alternative non-parametric tests were therefore used. The 
Mann-Whitney U-test is a non-parametric equivalent of the 
t-test, while the Kruskal-Wallis H-test can be used to test 
whether two or more independent samples come from the 
same population (13). Skewness-adjusted confidence inter- 
vals were constructed using a transformation involving an 
estimate of the skewness of the sample and the appropriate 
critical value from the standard normal distribution (14). 
Standard chi-squared tests were aiso used to compare 
proportions between two or more groups. The Kruskal- 
Wallis H-test and the standard chi-squared test both use the 
chi-squared statistic, although it is caiculated in a different 
manner. All chi-squared statistics relating to proportions 
are the result of the standard chi-squared test while other 
chi-squared statistics are the result of the Kruskal-Wallis 
H-test. 
Of the 128 585 patient records searched, 12 590 patients 
(9.8%) had been prescribed asthma-related medication in 
the previous 12 months. A total of 6582 patients (5.1%) 
were prescribed any type of inhaled corticosteroid device. 
Of these, 5704 patients (4.4%) were prescribed an Auto- 
haler, Diskhaler; MD1 or Turbuhaler as their sole cortico- 
steroid inhaler device during the study period. This data 
set included 86.7% of patients prescribed any cortico- 
steroid inhaler device and 45.3% of those prescribed any 
asthma-related medication. 
The age and sex distribution of the patient population 
according to the type of corticosteroid inhaie: device used is 
shown in Table 1. The mean age of patients prescribed the 
Diskhaler was 7 years younger than that of the overall 
study population. The relative proportions of patients 
prescribed each of the different corticosteroid inhaler 
devices by age group are shown in Fig. 1. 
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TABLE 1. Study population demographics by corticosteroid inhaler device 
Autohaler Diskhaler MD1 Turbuhaler Total 
n (“x7) n (%) n (%) n (%) n (%I 
Age bands 
~6 19 (4) 82 (8) 347 (12) 71 (5) 519 (9) 
6-18 146 (30) 509 (50) 359 (13) 325 (23) 1339 (24) 
19-49 162 (33) 190 (19) 1250 (45) 492 (36) 2094 (37) 
50+ 162 (33) 245 (24) 846 (30) 499 (36) 1752 (31) 
Total 489 1026 2802 1387 5704 
Male 198 (40) 494 (48) 1311 (47) 602 (43) 2605 (46) 
Female 291 (60) 532 (52) 1491 (53) 785 (57) 3099 (54) 
Mean age* 37 (8.6) 28 (18.0) 36 (49.1) 39 (24.3) 35 (100.0) 
*Kruskal-Wallis test: 11’ 159.621, df=3, P<O.OOl. 
Table 2 presents the numbers of asthma-related primary 
health-care consultations and prescriptions for each of the 
corticosteroid inhaler types prescribed, which were highest 
in the MD1 group and lowest in the Autohaler group. 
Table 3 shows the mean daily inhaled corticosteroid 
dose prescribed for each device which was lowest for the 
Autohaler (569 lug day- ‘), followed by the Diskhaler 
(638 pg day- ‘) and MD1 (655,~g day- ‘), and highest for 
the Turbuhaler (990,~~g day- ‘) group. Fig. 2 describes 
the mean inhaled corticosteroid dose for each device 
subdivided according to age group. 
The difference in inhaled corticosteroid dose according to 
the delivery system used was statistically significant for all 
age groups. Skewness-adjusted 95% confidence intervals 
presented in Fig. 3 show that the overall mean cortico- 
steroid doses prescribed for the Turbuhaler were 
significantly greater than for the other devices. 
Table 3 shows the proportion of patients treated with 
beta-agonists according to the type of corticosteroid inhaler 
used, which was lowest in the Autohaler group and highest 
in the MD1 group. Skewness-adjusted 95% confidence 
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FIG. 1. Proportion of patients by age band for each 
inhaler group. 0, ~6 years; n , 6-18 years; q , 19-49 years; 
N, 50+ years. 
intervals for patients prescribed a beta-agonist suggest that 
the mean daily salbutamol-equivalent dose was similar for 
the four corticosteroid inhaler groups, although the MD1 
and Diskhaler confidence intervals did not overlap. 
Table 3 also includes the proportion of patients pre- 
scribed oral steroids in each of the inhaler device groups. 
There was no significant difference between cumulative oral 
steroid doses prescribed in the Autohaler, MD1 and 
Turbuhaler groups k*=1.7, df=2, P=O.433). However, the 
Kruskal-Wallis test and skewness-adjusted confidence 
intervals suggested that the mean oral steroid dose pre- 
scribed for patients using the Diskhaler was significantly 
lower than for the other corticosteroid inhaler groups. 
A significantly greater proportion of patients aged 19-49 
years in the Turbuhaler and Diskhaler groups (29 and 23%, 
respectively) than in the MD1 group (4%) received at least 
one inhaled corticosteroid prescription including a daily 
dose higher than 1500,~g (see Table 4). Only two patients 
were prescribed the Autohaler in this dose range, which was 
insufficient for analysis of mean daily dose. Comparison of 
the proportion of patients prescribed aerosol inhalers 
(3.7%) and dry powder inhalers (27.4%) at doses higher 
than 1500 pg day - ’ was statistically significantly different 
(x2=256.27, df= 1, P<O.OOl). 
Discussion 
This retrospective study compared asthma-related 
prescription and consultation data for four different 
corticosteroid inhaler devices in the general practice setting, 
where an estimated 96% of asthmatic patients in New 
Zealand are treated (15). Data for analysis were collected 
from the computerized clinical records of a large patient 
population to provide more detailed information about 
asthma-prescribing patterns than could be obtained from 
traditional randomized controlled clinical trials. 
Mean daily inhaled corticosteroid doses in our study 
population varied according to the type of inhaler device 
prescribed. The mean daily dose for the Turbuhaler at 
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TABLE 2. Consultations and prescriptions by corticosteroid inhaler treatment (number/year) 
Autohaler Diskhaler MD1 Turbuhaler 
Mean 
total 
Asthma consultations 3.59 3.96 4.31 4.05 4.15 27.913 
All consultations 8.26 8.65 9.12 9.97 9.46 22.838 
Asthma prescriptions 4.42 5.86 6.45 5.24 5.88 101.283 
*All x2 values have 3 d! WO.001. 
TABLE 3. Mean doses and 95% confidence intervals for prescribed inhaled corticosteroids, inhaled beta-agonists and oral 
steroids 
Autohaler Diskhaler MD1 Turbuhaler x 2* 
Inhaled corticosteroid prescribing 
Inhaled corticosteroid dose by band age ~6 205 290 285 404 49.8, P<O,OOl 
6-18 415 442 453 659 94.4, P<O.OOl 
1949 620 904 658 1058 226.2, P<O.OOl 
50+ 700 955 889 1221 131.7, P<O.OOl 
Mean dose (,ug day - ‘) 569 638 655 990 414.7, P<O~OOl 
95% CI Lower 538 609 638 954 
Upper 605 670 673 1029 
Oral steroid prescribing 
Proportion patients 24% 16% 22% 21% 19.5, P<O.OOl 
Mean oral steroid dose (mg - ‘) year 572 445 794 844 20.0, P<O.OOl 
95% CI Lower 444 355 701 713 
Upper 841 589 920 1019 
Beta-agonist prescribing 
Proportion patients 67% 72% 71% 69% 45.3, P<O.OOl 
Mean beta agonist dose @g day - ‘) 438 565 467 484 1.8, P=O.620 
95% CI Lower 388 511 446 449 
Upper 550 638 489 528 
*All x2 values have 3 d! 
tSalbutamo1 dose equivalence based on 25O:lOO microgram efficacy ratio for terbutaline to salbutamol was estimated to 
compensate for the differing potency of these beta-agonists (10-12). 
990,ug was significantly higher than for other inhaler 
devices. Although the overall mean corticosteroid dose for 
the Diskhaler was similar to that of the MD1 and Auto- 
haler, analysis of the prescription data by age group showed 
that the mean dose for the Diskhaler in adults aged 1949 
years (904 pg day - ‘) was almost as high as for patients in 
the same age group prescribed the Turbuhaler (1058pg 
day- ‘). The low total Diskhaler dose results from the 
significantly greater number of younger patients prescribed 
lower doses with this device. 
Interestingly, our prescription data show a trend to 
higher prescribed doses of inhaled corticosteroid indepen- 
dent of inhaler type in older patients, who are also likely to 
have some degree of COAD associated with their asthma. 
As the data were analysed in broad age groups, specific 
comment for the nature of the apparent increase in corti- 
costeroid dose relative to age in a continuous distribution is 
1400, 7 
<6 6-18 19-49 
Patient age grcuups (years) 
FIG. 2. Mean daily prescribed dose of inhaled cortico- 
steroids by patient group. 0, Autohaler; q , Diskhaler; 
q a, MDI; N, Turbuhaler. 
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FIG. 3. Skewness-adjusted 95% CIs for inhaled cortico- 
steroid mean daily dose. Bands show range between 
upper and lower 95% CI limits. 
limited. This prescribing pattern is, however, of interest in 
view of the lack of evidence from controlled clinical trials of 
a clear therapeutic role for inhaled corticosteroids in the 
treatment of COAD (16). 
There are several possible reasons for the higher-dose 
dry-powder corticosteroid inhaler prescribing seen in our 
survey, including the higher dose presentations for these 
devices compared with the aerosol inhalers, the relative 
efficiency of the different devices and, in this country at 
least, advocacy of higher inhaled corticosteroid doses as 
first-line treatment of asthma in general. It is also possible 
that patients in this survey who were prescribed higher 
corticosteroid doses using the dry powder inhaler devices 
had more severe asthma and required higher corticosteroid 
doses to control their symptoms. However, as in controlled 
clinical trials, it is difficult to make a clear distinction 
between asthma severity and asthma control because com- 
monly used parameters of efficacy do not allow these 
components to be clearly separated (17). Moreover, in our 
study patients were not randomized to treatment. 
The finding of significantly higher prescribed corticoster- 
oid doses for the dry powder inhaler systems, in particular 
the Turbuhaler, was unexpected. There has been evidence 
from clinical studies suggesting improved drug delivery 
using the Turbuhaler (7,18,19), so it might have been 
reasonable to expect the doses prescribed for the 
Turbuhaler to be proportionately lower instead of higher 
than those for the other inhaler devices. Evidence from 
randomized controlled studies of the relative potency of 
budesonide and beclomethasone when delivered by MD1 
has previously suggested equivalent efficacy (20-22). The 
dose relationship with Diskhaler is not as well defined, 
although equivalence with beclomethasone MD1 has been 
demonstrated (20,21). 
Another unexpected finding was the relatively high 
proportion of adult patients in the Turbuhaler and 
Diskhaler groups who were regularly prescribed daily 
inhaled corticosteroid doses exceeding 1500,ug day-’ (29 
and 23%, respectively) in the absence of clear evidence of 
improved asthma control using any of these inhaler devices 
at higher doses (16,17,20-24). 
Only 73% of our asthmatic population overall had 
received beta-agonist prescriptions during the 12-month 
study period. A higher proportion of patients prescribed a 
corticosteroid MD1 received beta-agonist prescriptions 
than those prescribed an Autohaler or Turbuhaler, 
although the volume of beta-agonists prescribed was very 
similar for all treatment groups. Salbutamol-equivalent 
beta-agonist doses and oral steroid prescriptions were 
highest and lowest, respectively, in the Diskhaler group, 
and were clinically similar for the Autohaler, Turbuhaler 
and MD1 groups. 
The extent to which these prescription figures reflect 
actual prescribing in response to optimal asthma control 
using inhaled corticosteroids as first-line treatment, failure 
of medical record keeping, or patient usage of beta-agonists 
prescribed before the survey period is unknown. The 
frequency of beta-agonist prescribing indicated here is 
TABLE 4. Patients aged 1949 years with at least one inhaled corticosteroid prescription at a daily dose 2 1500,ug day- ’ 
Autohaler Diskhaler MD1 Turbuhaler X 2* 
Number of patients 
Percentage of patients 
Mean (years) age 
Consultations for asthma/year 
Inhaled corticosteroid prescribing 
- Mean dose (ug day ‘) 
Oral steroid prescribing 
Proportion 
~ Mean dose (mg ‘) year 
Beta-agonist prescribing 
Proportion 
Mean dose (ug day - ‘) 
*All x2 values have 2 df. 
21162 
1.2% 
441190 5011250 1431492 
23.2% 4.0% 29.1% 
35.1 36.2 34.2 
4.84 8.06 4.52 
1717 1948 1910 
25% 56% 29% 
896 1330 759 
89% 92% 82% 
1054 827 784 
1.9, P=O.382 
12.7, P=O.O02 
14.2, P=O.OOl 
14.2, P=O.OOl 
3.2, P=O.202 
3.5, P=O.170 
2.0, P=O.366 
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consistent with that previously reported for physician- 
diagnosed asthmatics in New Zealand and Australia (4). 
However, the proportion of asthma-related prescriptions 
which was actually used by patients is uncertain. Estimates 
of non-dispensing are variable, but a local report has 
suggested that approximately 105% of inhaled corticoster- 
oid and beta-agonist prescriptions for asthma are not 
collected (25). It should of course be borne in mind that 
even in controlled clinical trials perfect compliance with 
treatment is rarely attainable, inhaler devices are not always 
used correctly, and prescribed medicines are not necessarily 
taken according to directions (26628). Additionally, 
patients may have exercised some degree of self- 
management of their treatment and adjusted their own 
doses accordingly. 
Although it is difficult to draw any definitive conclusions 
from our research because of acknowledged methodo- 
logical limitations, these asthma-related prescription and 
consultation data afford a valuable insight into actual drug 
prescribing for asthma in a large patient population. Our 
principal findings are that significantly higher corticosteroid 
doses are prescribed for the dry powder devices compared 
with the aerosol inhalers and that the doses prescribed 
increase with age irrespective of inhaler device. These 
prescribing patterns raise questions about the extent to 
which the results of traditional comparative clinical studies 
of these inhaler devices can be extrapolated to actual 
medication usage by patients and prescribing in everyday 
clinical practice. 
High quality clinical databases of the type used in our 
survey are being increasingly advocated in the literature as 
an invaluable tool for ‘reality-based’ medical research 
(29-31), enabling more accurate assessment of the relevance 
of clinical trial results to clinical practice. More targeted use 
of databases such as that held by the RNZCGP Research 
Unit is likely to provide important information for clinical 
decision-making and lead to more rational use of health- 
care resources. Future asthma studies using this methodol- 
ogy could include analysis of prescription data for newer 
asthma medications, including fluticasone, which was not 
generally available in New Zealand at the time of this 
survey. 
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